Clinical trials: Rapid Response System
Opioid Overdose
Developing and Testing the Opioid Rapid Response System
This Phase I SBIR will develop and demonstrate the usability/feasibility of the Opioid Rapid Response System (OSSR) in order to reduce deaths and strain on emergency response systems from opioid overdoses.
- Trial name
- NCT04589676
- Testing
- Naloxone training
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Amyloidosis; Systemic, AL Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
- Trial name
- NCT06192979
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Jin Lu, MD
Rapid Response System, Vital Signs
The National Early Warning Score: Preceding Dynamics in the Score for Those Who Suffer an In-hospital Cardiac Arrest
To this date no clinical evaluation reports of the dynamics in the National Early Warning Score (NEWS) for those patients who suffer an in-hospital cardiac arrest, IHCA, exists.
- Trial name
- NCT03143062
- Testing
- NEWS
- Where
- Sweden
- Volunteers
- 381 people
- Sponsor
- Region Skane
Hepatitis C, Chronic
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1…
- Trial name
- NCT01353248
- Testing
- GS-5885, Tegobuvir, GS-9451
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 141 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection.
- Trial name
- NCT00629824
- Testing
- pegylated interferon alpha and plus ribavirin
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C
EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
The purpose of this study is to evaluate the effect of 48 vs 24 weeks of treatment with Peginterferon alfa-2b plus weight-based ribavirin on Sustained Virologic Response (SVR) and relapse rates in patients infected with genotype…
- Trial name
- EXACT-R(3) (NCT01095445)
- Testing
- Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
- Where
- 12 sites in Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Chronic
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis C (CHC) genotype 4 infection who…
- Trial name
- START 4 (NCT01606800)
- Testing
- PEG-IFN alfa-2b, ribavirin
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypersensitivity
Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response
BM32 is a product for immunotherapy of grass pollen allergies. It consists of 4 different recombinant proteins (BM321, BM322, BM325 and BM326) adsorbed on alhydrogel. This prospective, double-blind.
- Trial name
- NCT02643641
- Testing
- BM32
- Where
- Austria
- Volunteers
- 130 people
- Sponsor
- Biomay AG
Hepatitis C
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with…
- Trial name
- COPE-HCV (NCT00919633)
- Testing
- interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Hepatitis C, Chronic, Hepatitis C
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol.
- Trial name
- APEGIN (NCT00724854)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 1,146 people
- Sponsor
- Merck Sharp & Dohme LLC
Hospital Rapid Response Team, Hospital Medical Emergency Team
Deep Learning Based Early Warning Score in Rapid Response Team Activation
The objective of this study is to evaluate the safety and clinical usefulness of the Deep learning based Early Warning Score (DEWS).
- Trial name
- NCT04951973
- Testing
- Deep Learning Based Early Warning Score (DEWS)
- Volunteers
- 50,000 people
- Sponsor
- Seoul National University Hospital
Diabetes Mellitus
Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations
The purpose of this pilot study is to determine the utility of an algorithm for better glucose control in diabetic patients communicated via an App to help improve outcomes and reduce urgent care and ER visits as well as improve…
- Trial name
- GEMApp (NCT02336217)
- Testing
- Experimental Group instructions for glucose management via App
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Marshall University
Penicillin Allergy, Hypersensitivity, Immediate
Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels
The aim of this clinical trial is to analyze the negative predictive capacity and safety of risk-stratified direct drug provocation tests for patients with self-reported penicillin allergies.
- Conditions
- Penicillin Allergy, Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
- Trial name
- NCT06755281
- Testing
- Direct Oral challenge, standard of care
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Deniz Göcebe
ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
The available treatment for patients with mood and anxiety disorders have significant limitations (Rush, 2007; Denys and de Geus, 2005). There is a need to develop new treatments for people with these disorders.
- Trial name
- FASTMAS_Kor2 (NCT02218736)
- Testing
- CERC-501
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- Duke University
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack
Diagnosis of ON With or Without MS or NMOSD
This is both a prospective and retrospective study of patients with a known diagnosis of optic neuritis (ON) only, multiple sclerosis (MS) with ON, or neuromyelitis spectrum disorder (NMOSD) with ON.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression
- Trial name
- NCT04131764
- Testing
- Reflex (Brightlamp Inc., Purdue University)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Jagannadha R Avasarala
Pneumonia, Acute Pyelonephritis
NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
Rapid detection of microorganisms is a promising approach towards early administration of appropriate antibiotics for sepsis. This study aims to investigate the potential of a new NGS platform for the rapid diagnosis of…
- Conditions
- Pneumonia, Acute Pyelonephritis, Bacteremia, Biliary Tract Infection
- Trial name
- BIOARTE (NCT06141395)
- Testing
- NGS-based assay for bacterial identification
- Where
- 4 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Chronic Spontaneous Urticaria (CSU)
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines.
- Trial name
- NCT07665996
- Testing
- TLL-018
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Opioid Overdose
Opioid Rapid Response System: Naloxone Training in Communities
The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion.
- Trial name
- NCT06238128
- Testing
- Opioid Rapid Resonse System (ORRS) training, Non-active opioid overdose response training
- Where
- United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences